Cardiovascular Intervention and Therapeutics, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 27, 2025
Abstract Intravascular ultrasound (IVUS) provides precise anatomic information in coronary arteries including quantitative measurements and morphological assessment. To standardize the IVUS analysis current era, this updated expert consensus document summarizes methods of assessment images clinical evidence use percutaneous intervention.
Language: Английский
European Heart Journal, Journal Year: 2024, Volume and Issue: unknown
Published: Aug. 30, 2024
The global prevalence of obesity has more than doubled over the past four decades, currently affecting a billion individuals. Beyond its recognition as high-risk condition that is causally linked to many chronic illnesses, been declared disease per se results in impaired quality life and reduced expectancy. Notably, two-thirds obesity-related excess mortality attributable cardiovascular disease. Despite increasingly appreciated link between broad range manifestations including atherosclerotic disease, heart failure, thromboembolic arrhythmias, sudden cardiac death, underrecognized sub-optimally addressed compared with other modifiable risk factors. In view major repercussions epidemic on public health, attention focused population-based personalized approaches prevent weight gain maintain healthy body from early childhood throughout adult life, well comprehensive loss interventions for persons established obesity. This clinical consensus statement by European Society Cardiology discusses current evidence epidemiology aetiology obesity; interplay obesity, factors conditions; management patients strategies lifestyle changes, interventional procedures, anti-obesity medications particular focus their impact cardiometabolic outcomes. document aims raise awareness factor provide guidance implementing evidence-based practices prevention optimal within context primary secondary prevention.
Language: Английский
Citations
49
New England Journal of Medicine, Journal Year: 2024, Volume and Issue: unknown
Published: Nov. 17, 2024
BackgroundInflammation is associated with adverse cardiovascular events. Data from recent trials suggest that colchicine reduces the risk of events.MethodsIn this multicenter trial a 2-by-2 factorial design, we randomly assigned patients who had myocardial infarction to receive either or placebo and spironolactone placebo. The results are reported here. primary efficacy outcome was composite death causes, recurrent infarction, stroke, unplanned ischemia-driven coronary revascularization, evaluated in time-to-event analysis. C-reactive protein measured at 3 months subgroup patients, safety also assessed.ResultsA total 7062 104 centers 14 countries underwent randomization; time analysis, vital status unknown for 45 (0.6%), information most likely missing random. A primary-outcome event occurred 322 3528 (9.1%) group 327 3534 (9.3%) over median follow-up period years (hazard ratio, 0.99; 95% confidence interval [CI], 0.85 1.16; P=0.93). incidence individual components appeared be similar two groups. least-squares mean difference levels between months, adjusted according baseline values, −1.28 mg per liter (95% CI, −1.81 −0.75). Diarrhea higher percentage than (10.2% vs. 6.6%; P<0.001), but serious infections did not differ groups.ConclusionsAmong treatment colchicine, when started soon after continued years, reduce (death revascularization). (Funded by Canadian Institutes Health Research others; CLEAR ClinicalTrials.gov number, NCT03048825.)
Language: Английский
Citations
34
European Journal of Preventive Cardiology, Journal Year: 2024, Volume and Issue: unknown
Published: Aug. 30, 2024
The global prevalence of obesity has more than doubled over the past four decades, currently affecting a billion individuals. Beyond its recognition as high-risk condition that is causally linked to many chronic illnesses, been declared disease per se results in impaired quality life and reduced expectancy. Notably, two-thirds obesity-related excess mortality attributable cardiovascular disease. Despite increasingly appreciated link between broad range manifestations including atherosclerotic disease, heart failure, thromboembolic arrhythmias, sudden cardiac death, underrecognized sub-optimally addressed compared with other modifiable risk factors. In view major repercussions epidemic on public health, attention focused population-based personalized approaches prevent weight gain maintain healthy body from early childhood throughout adult life, well comprehensive loss interventions for persons established obesity. This clinical consensus statement by European Society Cardiology discusses current evidence epidemiology aetiology obesity; interplay obesity, factors conditions; management patients strategies lifestyle changes, interventional procedures, anti-obesity medications particular focus their impact cardiometabolic outcomes. document aims raise awareness factor provide guidance implementing evidence-based practices prevention optimal within context primary secondary prevention.
Language: Английский
Citations
16
Biomedicines, Journal Year: 2025, Volume and Issue: 13(1), P. 135 - 135
Published: Jan. 8, 2025
Cardiovascular-Kidney-Metabolic syndrome, introduced by the American Heart Association in 2023, represents a complex and interconnected spectrum of diseases driven shared pathophysiological mechanisms. However, this framework notably excludes liver-an organ fundamental to metabolic regulation. Building on concept, Cardiovascular-Renal-Hepatic-Metabolic (CRHM) syndrome incorporates liver's pivotal role disease spectrum, particularly through its involvement via dysfunction-associated steatotic liver (MASLD). Despite increasing prevalence CRHM unified management strategies remain insufficiently explored. This review addresses following critical question: How can novel anti-diabetic agents, including sodium-glucose cotransporter-2 inhibitors (SGLT2is), glucagon-like peptide-1 receptor agonists (GLP-1RAs), dual gastric inhibitory polypeptide (GIP)/GLP-1RA, offer an integrated approach managing beyond boundaries traditional specialties? By synthesizing evidence from landmark clinical trials, we highlight paradigm-shifting potential these therapies. SGLT2is, such as dapagliflozin empagliflozin, have emerged cornerstone guideline-directed treatments for heart failure (HF) chronic kidney (CKD), providing benefits that extend glycemic control are independent diabetes status. GLP-1RAs, e.g., semaglutide, transformed obesity enabling weight reductions exceeding 15% improving outcomes atherosclerotic cardiovascular (ASCVD), diabetic CKD, HF, MASLD. Additionally, tirzepatide, GIP/GLP-1RA, enables unprecedented loss (>20%), reduces risk over 90%, improves HF with preserved ejection fraction (HFpEF), MASLD, obstructive sleep apnea. moving organ-specific approach, propose integrates agents into holistic syndrome. paradigm shift moves away fragmented, organ-centric toward more fostering collaboration across specialties marking progress precision cardiometabolic medicine.
Language: Английский
Citations
6
Journal of the American College of Cardiology, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 1, 2025
Language: Английский
Citations
3
The Lancet, Journal Year: 2025, Volume and Issue: 405(10475), P. 329 - 337
Published: Jan. 1, 2025
Language: Английский
Citations
3
EuroIntervention, Journal Year: 2025, Volume and Issue: 21(3), P. e161 - e170
Published: Jan. 29, 2025
Safe deferral of revascularisation is a key aspect physiology-guided percutaneous coronary intervention (PCI). While recent evidence gathered in the FAVOR III Europe trial showed that quantitative flow ratio (QFR) guidance did not meet non-inferiority to fractional reserve (FFR) guidance, it remains unknown if QFR might have specific value deferral. We aimed evaluate safety based on as compared with FFR. Patients randomised whom PCI was deferred at least one artery, or FFR>0.80, were included present substudy. The primary outcome 1-year rate major adverse cardiac events (MACE), results reported for two subsets patients: (1) any study lesion and (2) complete A total 523 patients (55.2%) group 599 (65.3%) FFR had Of these, 433 (82.8%) 511 (85.3%) patients, respectively, In "complete deferral" patient group, occurrence MACE significantly higher QFR-deferred FFR-deferred (24 [5.6%] vs 14 [2.8%], adjusted hazard [HR] 2.07, 95% confidence interval [CI]: 1.07-4.03; p=0.03). subgroup "any deferral", 5.6% 3.6% (QFR FFR), HR 1.55, CI: 0.88-2.73; p=0.13. QFR-based artery resulted incidence FFR-based
Language: Английский
Citations
2
JACC Asia, Journal Year: 2025, Volume and Issue: 5(1), P. 59 - 70
Published: Jan. 1, 2025
Coronary physiology measured by fractional flow reserve (FFR) is superior to angiography for assessing the efficacy of percutaneous coronary intervention (PCI). Yet, clinical adoption post-PCI FFR limited. Murray law-based quantitative ratio (μQFR) may represent a promising alternative, as it can quickly compute from single angiographic view. The authors aimed investigate potential role μQFR in predicting outcomes. This was post hoc blinded analysis FLAVOUR trial. Patients with angiographically intermediate lesions randomized 1:1 receive or intravascular ultrasound-guided PCI were included. Post-PCI assessed successfully stented vessels, Suboptimal physiological outcome defined priori <0.90. primary endpoint 2-year target vessel failure, including cardiac death, myocardial infarction, and revascularization. Secondary endpoints included diagnostic concordance pre-PCI FFR-guidance arm. analyzed 806 vessels 777 participants (feasibility 97.0% [806 831]). identified 24.7% (199 806) <0.90 associated higher risk failure (6.1% [12 199] vs 2.7% [16 607]; HR: 2.45 [95% CI: 1.14-5.26]; P = 0.022). Pre-PCI obtained 877 919 95.4%), showing 90% accuracy, 82% sensitivity, 94% specificity identifying physiologically significant stenosis ≤0.80. In patients who underwent contemporary imaging guidance, lower values predict subsequent adverse events. (Fractional FLow Reserve And IVUS Clinical OUtcomes With InteRmediate Stenosis [FLAVOUR]; NCT02673424).
Language: Английский
Citations
2
Journal of Nuclear Cardiology, Journal Year: 2025, Volume and Issue: unknown, P. 102140 - 102140
Published: Jan. 1, 2025
Language: Английский
Citations
2
European Heart Journal, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 10, 2025
Journal Article Functional coronary assessment in angina with intermediate stenosis: the #FullPhysiology approach Get access Antonio Maria Leone, Leone Center of Excellence Cardiovascular Sciences, Ospedale Isola Tiberina—Gemelli Isola, Via di Ponte Quattro Capi 39, 00186 Rome, ItalyUniversità Cattolica del Sacro Cuore, Largo Agostino Gemelli 1, 00168 Italy Corresponding author. Email: [email protected], protected] https://orcid.org/0000-0002-1276-9883 Search for other works by this author on: Oxford Academic PubMed Google Scholar Domenico Galante, Galante Andrea Viceré, Viceré Università Marrone, Marrone Cardiology Unit, Azienda Ospedaliero Universitaria Ferrara, Aldo Moro 8, 44124 Cona, Filippo Verardi, Verardi Chiara Giuliana, Giuliana Ciro Pollio Benvenuto, Benvenuto Vincenzo Viccaro, Viccaro Simona Todisco, Todisco Erriquez, Erriquez ... Show more Simone Biscaglia, Biscaglia https://orcid.org/0000-0001-6074-2370 Cristina Aurigemma, Aurigemma Department Fondazione Policlinico IRCCS, https://orcid.org/0000-0001-6391-422X Enrico Romagnoli, Romagnoli https://orcid.org/0000-0003-1611-7708 Rocco Montone, Montone Michele Basile, Basile ItalyAlta Scuola Economia e Management dei Sistemi Sanitari, Eugenio Di Brino, Brino Rumi, Rumi Gennaro Capalbo, Capalbo Carlo Trani, Trani ItalyDepartment Francesco Burzotta, Burzotta Crea, Crea Italo Porto, Porto Disease IRCCS Policlinic Hospital San Martino, Italian Network, Rosanna Benzi 10, 16132 Genoa, Internal Medicine, University https://orcid.org/0000-0002-9854-5046 Gianluca Campo European Heart Journal, ehae926, https://doi.org/10.1093/eurheartj/ehae926 Published: 10 January 2025 history Received: 11 July 2024 Revision received: 06 October Accepted: 17 December
Citations
2